Aminocapronic acid on 1 гр

General characteristics. Structure:

International and chemical names: aminocapronic acid; 6-aminohexane acid;
main physical and chemical properties: powder of inodorous white color; 
structure: 1 package contains aminocapronic acid 1 g; 

Pharmacological properties:

Pharmacodynamics. The specific styptic means applied at the bleedings caused by increase in a fibrinolysis.
The mechanism of specific action is caused by competitive oppression of plasminogen activators and partial oppression of activity of plasmin (in high doses), and also inhibition of biogenic polypeptides – kinin. 
The activating action of Streptokinasa, urokinase and fabric kinases on processes of a fibrinolysis oppresses, neutralizes effects of kallikrein, trypsin and hyaluronidase, reduces permeability of capillaries.
Shows moderate antiallergic and antishock activity; increases anti-toxic function of a liver. Brakes the proteolytic activity associated with an influenza virus, inhibits proteolytic activity of hemagglutinin. Improves some cellular and humoral indicators of specific and nonspecific protection at respiratory viral infections.

Pharmacokinetics. After intake it is quickly soaked up in upper parts of digestive tract. The maximum concentration in blood at adults and teenagers is reached in 2 – 3 hour. Practically does not contact blood proteins. Partially (10 – 15%) it biotransformirutsya in a liver; other part is removed by kidneys preferential in not changed look. Per day about 60% of the entered dose (are brought out of an organism at normal function of kidneys).
At disturbance of urinary function drug cumulation is possible.

Indications to use:

Prevention and treatment of parenchymatous bleedings, hemorrhages from mucous membranes, menorrhagias, bleedings from erosion and stomach ulcers and intestines. Prevention of bleedings at liver, lungs, pancreas operations. Different types of a hyper fibrinolysis, including connected using thrombolytic drugs and massive transfusion of stored blood. As symptomatic means – bleeding caused by thrombocytopenia and qualitative inferiority of thrombocytes (dysfunctional thrombocytopenia). 

Route of administration and doses:

Appoint inside, in time or after food, having dissolved powder in sweet water or washing down with it. The daily dose for adults is divided into 3 – 6 receptions, for children – into 3 – 5 receptions.
Moderately expressed increase in fibrinolitic activity. The adult usually appoint 5 – 24 g (5 – 24 packages) in a daily dose. 
For children till 1 year the single dose makes 0,05 g/kg of body weight (but no more than 1 g). The daily dose for children makes: aged till 1 year – 3 g (3 packages), 2 – 6 years – 3 – 6 g (3 – 6 packages), 7 – 10 years – 6 – 9 g (6 – 9 packages). For teenagers the maximum daily dose – 10 – 15 g (10 – 15 packages). 
Acute bleedings (including gastrointestinal). Adult appoint 5 g (5 packages), then 1 g (1 package) each hour (within no more 8th hour) to a full stop of bleeding. A daily dose for children at acute blood losses: aged till 1 year – 6 g (6 packages), 2 – 4 years – 6 – 9 g (6 – 9 packages), 5 – 8 years – 9 – 12 g (9 – 12 packages), 9 – 10 years – 
18 g (18 packages).
Subarachnoidal hemorrhage. The adult appoint 6 – 9 g (6 – 9 packages) in a daily dose.
Traumatic hyphema. Every appoint in a dose 0,1 g/kg of body weight the 4th hour (but no more 
24 g/days) within 5 days.
The metrorrhagias associated with intrauterine means. Appoint on 3 g (3 packages) every the 6th hour. 
Prevention and stop of bleeding at dental interventions. The adult appoint 2 – 3 g (2 – 3 packages) of 3 - 5 times a day.
For adults an average daily dose – 10 – 18 g (10 – 18 packages), the maximum daily dose – 24 g (24 packages).
Course of treatment of 3 - 14 days.
Duration of treatment is defined individually and depends on disease severity. According to indications repeated courses of treatment are possible.

Features of use:

With care appoint at heart diseases, a liver and/or renal failure.
Use of drug at a hamaturia is not recommended (in connection with danger of development of an acute renal failure).
At prolonged use (more than 6 days) of high doses (more than 24 g a day for adults) emergence of hemorrhages owing to braking of aggregation and adhesion of thrombocytes is possible.
At menorrhagias reception from the first to the last day monthly is effective.
During therapy drug recommends check of fibrinolitic activity of blood and level of fibrinogen. 
Use during pregnancy and feeding by a breast. Drug is contraindicated at pregnancy. Use for women for the purpose of prevention of the raised blood loss at childbirth since emergence of tromboembolic episodes is possible is inexpedient. In need of use in the period of a lactation feeding by a breast should be stopped.
Influence on a possibility of control of vehicles and mechanisms. During treatment it is necessary to abstain from control of motor transport and performance of potentially dangerous types of activity owing to possible side reactions (dizziness, etc.

Side effects:

From cardiovascular system: orthostatic hypotension, subendocardial hemorrhage, bradycardia, arrhythmias. From system of digestion: nausea, diarrhea. From system of a blood coagulation: at prolonged use (more than 6 days) of high doses (for adults – more than 24 g a day) – hemorrhages. From the central nervous system: headache, dizziness, sonitus, spasms. Other: catarral phenomena of upper parts of respiratory tracts, skin rash, myoglobinuria, рабдомиолиз, acute renal failure.
By-effects are rare and dozozavisimy; at a dose decline they usually disappear.

Interaction with other medicines:

At intake it is well combined with thrombin. The effect of drug is weakened by antiagregant and anticoagulants of direct and indirect action. Combined use with estrogensoderzhashchy contraceptives, blood-coagulation factors of IX increases risk of thromboembolisms.

Contraindications:

The increased individual sensitivity to aminocapronic acid, tendency to fibrinferments and embolisms, all hereditary and secondary thrombophilias, a syndrome of the disseminated intravascular coagulation, a gross hematuria, heavy renal failures, pregnancy, a lactation.

Overdose:

Symptoms: strengthening of by-effects, formation of blood clots, embolisms. At prolonged use development of opposite effect – a hemorrhage is possible. Treatment: drug withdrawal, symptomatic therapy.

Storage conditions:

To store in the dry place at a temperature from 8 °C to 25 °C. To store in the place, unavailable to children.
Period of validity 2 years.

Issue conditions:

According to the recipe

Packaging:

On 1 g of powder in packages No. 1 or in the packages coupled No. 2.